论文部分内容阅读
目的探讨三氧化二砷(AS2O3)、全反式维甲酸(ATRA)联合化疗方案对治疗急性早幼粒细胞白血病(APL)的疗效。方法 32例APL患者经联合诱导后,再对其进行巩固、维持治疗。结果 32例患者持续缓解率(CCR)为87.5%,5年预计OS和RFS分别为92.3%、88.2%未发现严重不良反应。结论 APL完全缓解患者巩固强化治疗后用ATRA、AS2O3与化疗联合维持治疗,总体生存率高,安全性好,值得临床推广。
Objective To investigate the efficacy of combination of arsenic trioxide (AS2O3) and all-trans retinoic acid (ATRA) in the treatment of acute promyelocytic leukemia (APL). Methods 32 cases of APL patients induced by the joint, and then consolidate and maintain treatment. Results The 32 patients had a sustained response rate (CCR) of 87.5%. The 5-year OS and RFS were 92.3% and 88.2%, respectively. No serious adverse reactions were found. Conclusion APL patients with complete remission consolidation therapy with ATRA, AS2O3 and chemotherapy combined with maintenance therapy, the overall survival rate, safety, and worthy of clinical promotion.